One To Watch

Seres Therapeutics

Company Overview

A Cambridge-based microbiome company that pioneered the first FDA-approved oral live biotherapeutic, Seres Therapeutics is now rebuilding around SER-155, a Breakthrough Therapy-designated asset targeting infections in immunocompromised patients. Having divested VOWST — its landmark C. difficile product — to Nestlé Health Science in 2024, Seres is now a leaner, single-asset clinical-stage company. The strategic pivot from commercialization back to development is the defining tension: the company has proof of concept in spades, but needs to secure funding to advance its Phase II program before runway expires in early 2027.

Headquarters and Global Presence

Seres Therapeutics is headquartered in Cambridge, Massachusetts, the center of US biotech. Following a lease restructuring in June 2026 to reduce costs, the company operates with a reduced footprint consistent with its clinical-stage focus.

Founding and History

Seres Therapeutics was founded in 2012 and went public on NASDAQ (ticker: MCRB) in 2015. Its Phase III ECOSPOR III study demonstrated that SER-109 — later branded VOWST — prevents recurrent C. difficile infection by rapidly seeding beneficial gut microbes that produce short-chain fatty acids disrupting the C. difficile lifecycle. FDA approval of VOWST in 2023 marked a historic first for oral microbiome medicine. Seres divested VOWST to Nestlé Health Science in 2024 to focus capital on SER-155.

Therapy Areas and Focus

Seres is now focused on immunocompromised patient populations where gut microbiome disruption drives life-threatening infection risk. The primary target indication for SER-155 is allogeneic hematopoietic stem cell transplant (allo-HCT), a setting where antibiotic exposure and conditioning regimens devastate the gut microbiome and create vulnerability to bloodstream infections and graft-versus-host disease. A secondary program examines immune checkpoint inhibitor-related enterocolitis, linking the platform to immuno-oncology. Both indications represent high unmet need with no approved microbiome-based intervention.

Technology Platforms and Modalities

Seres designs live biotherapeutics — orally administered consortia of defined bacterial strains selected to reconstitute protective microbiome function. Rather than delivering a single probiotic strain, the approach uses rationally composed communities intended to establish durable colonization and drive specific metabolic and immune outputs. The VOWST experience validated the core principle: beneficial microbes outcompeting pathogens and generating fatty acids that suppress C. difficile spore germination. SER-155 applies the same design logic to broader infection prevention in immunosuppressed hosts.

Key Pipeline and Programs

SER-155 is the sole active clinical asset. It is an oral live biotherapeutic product comprising a defined bacterial consortium, designed to reduce the incidence of infections — including bloodstream infections caused by antibiotic-resistant organisms — in patients undergoing allo-HCT. The program holds FDA Breakthrough Therapy designation and Fast Track designation, reflecting the agency's view of both the unmet need and the early clinical signal. A company-sponsored Phase II trial is Phase 2-ready but pending partnership or financing to initiate. In parallel, an investigator-sponsored trial is evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis, an increasingly recognized complication of cancer immunotherapy where gut microbiome disruption is mechanistically central. No NCT identifiers for the company-sponsored Phase II were disclosed in available sources, though the IST is ongoing.

Recent Developments

On 5 June 2026, Seres announced a $25 million deal with Nestlé Health Science, under which Nestlé buys out all potential future VOWST net-sales milestone payments in two equal installments scheduled for July and October 2026. Simultaneously, Seres restructured its Cambridge lease to cut operating costs. Together, the transactions extend the company's projected cash runway into the first quarter of 2027 — buying roughly nine additional months to secure a partnership or financing for SER-155's Phase II. The transaction is as much a clock-reset as a vote of confidence: Seres has real science but a narrow window.

Key Personnel

Eric Shaff serves as President and Chief Executive Officer, having guided the company through both the VOWST approval and its subsequent divestiture to Nestlé. Lisa von Moltke serves as Chief Medical Officer; she brings extensive clinical pharmacology and drug development expertise from prior roles in large pharma. The leadership team is structured around the clinical advancement of SER-155 and securing the capital needed to execute the Phase II program.

Strategic Partnerships

The defining recent transaction is the June 2026 milestone buyout with Nestlé Health Science, worth $25 million, which severs the last financial tie to VOWST and consolidates Seres's focus on SER-155. The original VOWST divestiture to Nestlé in 2024 generated proceeds that funded operations through the pivot. Seres is actively seeking a development partner or investor to fund the SER-155 Phase II program in allo-HCT — that search is the company's principal strategic imperative.

FAQ Section

Seres divested VOWST to Nestlé Health Science in 2024 because commercializing a novel therapeutic category — with the infrastructure investment that requires — was consuming capital the company judged better deployed in clinical development. The sale effectively converted a revenue-generating asset into runway and strategic clarity. Seres is now a pure clinical-stage company again, with SER-155 as its entire bet; the logic is that the microbiome platform's highest-value application is in immunocompromised patients, not the already-competitive C. difficile market.

Patients undergoing allo-HCT receive intensive conditioning regimens and prolonged antibiotics that deplete the gut microbiome, creating a window of vulnerability to antibiotic-resistant organisms capable of translocating from the gut into the bloodstream. SER-155 is a defined bacterial consortium administered orally to reconstitute that protective microbial layer before and during the transplant period. The hypothesis — supported by mechanistic data from the C. difficile program — is that a colonization-competent community can outcompete pathogens and modulate local immune responses that would otherwise drive infection and graft-versus-host disease.

Unlike donor-derived fecal microbiota products such as Ferring's Rebyota or Seres's own VOWST, SER-155 is a rationally designed consortium of defined strains, manufactured to a consistent specification rather than sourced from screened donors. That consistency matters particularly in immunocompromised patients, where donor-derived products carry residual pathogen transmission risk and batch-to-batch variability is a safety and regulatory concern. The defined-consortium approach also enables mechanistic characterization of which strains are driving efficacy — a foundation for iterative improvement that fecal-derived products cannot easily offer.

SER-155 has completed Phase I evaluation and holds both FDA Breakthrough Therapy and Fast Track designations — regulatory signals that the agency views the early data and unmet need favorably. A company-sponsored Phase II trial in allo-HCT patients is described as Phase 2-ready but has not initiated, contingent on Seres securing partnership or additional financing. An investigator-sponsored trial evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis is ongoing, providing an additional data stream without requiring Seres to fund the full study.

The current pipeline is effectively SER-155 across two indications: infectious complications in allo-HCT and immune checkpoint inhibitor-related enterocolitis. Both sit at the intersection of microbiome biology and immunology — a deliberate positioning that aligns the company's platform competence with high-value oncology-adjacent settings. Expansion beyond SER-155 is premature given the current funding constraints; Seres's stated priority is getting SER-155 into Phase II before exploring broader pipeline development.

The June 2026 Nestlé milestone buyout, combined with the lease restructuring, extends cash runway into Q1 2027 — roughly nine months from the announcement. "Phase 2-ready" means the trial design, regulatory alignment, and manufacturing are sufficiently mature to begin enrollment once funding is in place, but the study has not yet started. That distinction matters: the clock is running, and Seres needs a partnership, licensing deal, or equity raise before runway expires or the window to maintain momentum in this indication closes.

The key watchpoints heading into 2027 are:

Funding announcement: securing a partner or financing to initiate the SER-155 Phase II in allo-HCT is the single most important near-term catalyst; failure to do so before Q1 2027 creates a critical viability question.
IST data from the checkpoint inhibitor enterocolitis trial: any signal here broadens the asset's commercial narrative and could attract oncology-focused partners.
Nestlé milestone payments: the two $12.5 million installments (July and October 2026) are contracted cash receipts — their arrival sustains runway as planned.
Competitive landscape in allo-HCT microbiome: Vedanta Biosciences and others are active in defined-consortium live biotherapeutics; a competitor Phase II readout in adjacent indications could reframe the differentiation story positively or negatively.
Regulatory designation leverage: Breakthrough Therapy status is a meaningful negotiating tool in partnership discussions but does not guarantee a deal.

Want to Update your Company's Profile?